CFTX 1554
Alternative Names: CFTX-1554Latest Information Update: 06 Mar 2023
At a glance
- Originator Confo Therapeutics
- Class Non-opioid analgesics; Small molecules
- Mechanism of Action Angiotensin type 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Neuropathic pain
Most Recent Events
- 02 Mar 2023 CFTX 1554 licensed to Eli Lilly and Company worldwide
- 10 Mar 2022 Phase-I clinical trials in Neuropathic pain (In volunteers) in Netherlands (PO) (NCT05260658)
- 15 Dec 2021 Confo Therapeutics has patent protection for methods for screening GPCRs using ConfoBodies®, GPCR-ConfoBody® complexes, developments of the ConfoBody® platform in ConfoScreen®, ConfoSensor®, ConfoChimer™ and ConfoStructure™ technologies in USA and European Union